AzTrials
AzTrials

Gallstone DiseaseNCT07453186

Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting

A study testing Diagnostic procedures in people with Gallstone Disease and Ultrasonic Diagnosis, run by Esbjerg Hospital - University Hospital of Southern Denmark at 1 site in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems. Approximately one in five patients later requires a second operation to remove the gallbladder. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Diagnostic procedures
Could I receive a placebo?
No, everyone receives an active treatment
How many people
130 participants
Where
1 siteDenmark
Study dates
1 Apr 2026to 1 Mar 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Scheduled for bariatric surgery
  • Able to provide informed consent

Who cannot join

  • Previous cholecystectomy
  • Previous biliary surgery
  • Previous liver surgery
  • Inability to provide informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Denmark1 site, 1 recruiting
  • Esbjerg og Grindsted Sygehus

    Esbjerg, 6700

    Benjamin Petersen, M.D., + 45 79 18 57 14, benjamin.drejer.petersen@rsyd.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting: Utility and Diagnostic Accuracy

Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems.

Approximately one in five patients later requires a second operation to remove the gallbladder. This type of surgery carries a higher risk of complications and reoperations compared with gallbladder surgery performed in the general population.

Read more

Preventive treatment may help reduce this risk. One option is medical treatment with Ursochol, which has been shown to lower the risk of developing gallstones after bariatric surgery. However, this treatment is only effective in patients who have not already developed gallstones before surgery.

This means patients need a reliable preoperative ultrasound examination of the gallbladder. Unfortunately, performing ultrasound can be technically challenging in patients with obesity, making it harder to detect small stones or other abnormalities.

The goal is therefore to improve the examination of the gallbladder in patients undergoing bariatric surgery in order to better identify who may benefit from preventive treatment.

The study

The investigators are comparing two types of ultrasound examination of the gallbladder:

  • Standard ultrasound performed on the outside of the abdomen using a handheld probe.
  • Laparoscopic ultrasound performed during bariatric surgery using a small ultrasound probe placed inside the abdomen, typically placed on the liver near the gallbladder.

It is of interest to find out whether the ultrasound performed during surgery finds more:

  • Gallstones
  • Sludge
  • Small stones (microlithiasis)
  • Thickening of the gallbladder wall

By improving detection, the investigators aim to better guide preventive treatment and reduce the need for future gallbladder surgery.

Read the detailed description
  1. TITLE Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting
  2. BACKGROUND AND RATIONALE 2.1 Clinical Background Bariatric surgery is an established and effective treatment for severe obesity. In Denmark, approximately 2,000 bariatric procedures are performed annually. These procedures result in significant and intended weight loss and improvement in metabolic comorbidities. However, rapid weight loss is associated with an increased risk of gallstone formation. Gallstone disease is one of the most common postoperative complications following bariatric surgery. Approximately 10% of patients undergo cholecystectomy within two years after surgery, increasing to up to 20% within ten years. Importantly, cholecystectomy in patients who previously underwent bariatric surgery is associated with:
  • Increased risk of surgical complications
  • Higher rates of reoperation
  • More technically complex procedures
  • Increased risk of bile duct injury In patients with Roux-en-Y gastric bypass, management of biliary tract disease is particularly challenging due to altered gastrointestinal anatomy, which complicates endoscopic access (e.g., ERCP). 2.2 Preventive Treatment and Diagnostic Challenge Prophylactic treatment with ursodeoxycholic acid (Ursochol) has been shown to significantly reduce the risk of symptomatic gallstone disease in the first two years after bariatric surgery. However:
  • Ursochol is only effective in patients who do not already have gallstones.
  • Therefore, accurate preoperative detection of gallstones is essential. Conventional transabdominal ultrasound (TAUS) is the standard imaging modality for gallbladder evaluation. However, in patients with severe obesity:
  • Ultrasound penetration is limited
  • Image quality may be reduced
  • Small stones and sludge may be overlooked
  • Sensitivity may be as low as 62-68% Thus, diagnostic uncertainty may lead to:
  • Under-treatment (missed stones)
  • Over-treatment (inappropriate prophylaxis)
  • Inconsistent national implementation 2.3 Rationale for Laparoscopic Ultrasound (LUS) Laparoscopic ultrasound (LUS) allows:
  • Direct placement of the probe on the liver surface
  • Shorter acoustic distance
  • Higher image resolution
  • Potentially improved detection of subtle pathology
  • Fewer hospital visits for the patients prior to surgery Only one prior study has directly compared TAUS and LUS in this population. That study suggested higher overall pathology detection with LUS, but lacked:
  • Histological confirmation
  • Sample size justification
  • Assessment of microlithiasis
  • Gallbladder wall measurements
  • Formal evaluation of interobserver agreement within each ultrasound modality Therefore, a well-designed prospective paired diagnostic study is warranted.
  1. OBJECTIVES

3.1 Primary Objective To compare the diagnostic detection rate of gallbladder pathology between transabdominal ultrasound (TAUS) and laparoscopic ultrasound (LUS) in patients undergoing bariatric surgery.

3.2 Secondary Objectives

  1. To evaluate interobserver agreement within TAUS and LUS examinations
  2. To compare examination time between modalities
  3. To assess image quality
  4. HYPOTHESES
  5. Laparoscopic ultrasound detects significantly more gallbladder pathology than transabdominal ultrasound.
  6. LUS has lower interobserver variability compared to TAUS.
  7. STUDY DESIGN Prospective observational diagnostic comparative study with paired within-patient design.

Each participant undergoes:

  • Two independent TAUS examinations
  • Two independent LUS examinations

All examinations are performed blinded and independently.

No randomization is performed.

No experimental interventions are introduced.

  1. STUDY PROCEDURES

6.1 Preoperative Phase

Participants undergo:

  • Two transabdominal ultrasounds
  • Performed on the same day
  • By two independent radiologists/sonographers
  • Blinded to each other's findings

6.2 Intraoperative Phase

During planned bariatric surgery:

  • Two surgeons independently perform laparoscopic ultrasound
  • Probe placed directly on liver surface
  • Examinations blinded
  • Adds 5-10 minutes to procedure
  1. STATISTICAL ANALYSIS PLAN

7.1 Primary Analysis McNemar's test for paired binary outcomes.

Significance level: 0.05 (one-sided)

Power: 90%

7.2 Sample Size Calculation Sample size was calculated for a paired binary comparison of the composite gallbladder pathology outcome between transabdominal ultrasound (TAUS) and laparoscopic ultrasound (LUS) using a one-sided McNemar test (α=0.05, power=90%). The sample size was calculated in two ways. Under one model, we assumed the detection rates of 25% for TAUS and 35% for LUS with an estimated between-modality correlation of 0.70. In the second model, we assumed discordant proportions of 0.10 (TAUSnegative / LUSpositive) and 0.01 (TAUSpositive / LUSnegative). Approximately in both models, the required sample size was 117 evaluable paired patients; allowing for 10% dropout/non-evaluable cases, we will enroll 130 patients in total.

7.3 Secondary Analyses • Interobserver agreement: Cohen's kappa

  • Subgroup analyses (BMI strata, bariatric surgery)

All analyses conducted in STATA.

  1. ETHICAL CONSIDERATIONS

8.1 Risk Assessment Both TAUS and LUS examinations are well known diagnostic modalities without any known risk profile. The LUS procedure will add 5-10 minutes of additional surgery, which seems reasonable.

Overall, the risk of the examinations are considered minimal.

8.2 Potential Benefits • Improved diagnostic precision

  • Better patient selection for preventive treatment
  • Reduced need for future gallbladder surgery
  • Simpler ultrasound examinations
  1. DATA MANAGEMENT
  • Data stored in secure SharePoint research environment and REDCap Systems
  • GDPR compliant
  • Restricted access
  • Registered internally at hospital
  1. DISSEMINATION

Results will be:

  • Published regardless of outcome
  • Submitted to peer-reviewed journals
  1. FUNDING
  • Part of a PhD program
  • No funding from private companies
  • Additional funding sought from regional and national foundations
  1. EXPECTED IMPACT

If LUS demonstrates superior diagnostic performance:

  • It may guide selective prophylactic therapy
  • It may reduce long-term gallbladder morbidity
  • It may standardize diagnostic workup

This study has direct translational relevance to clinical practice.

Being tested
Diagnostic procedures
Keywords
Bariatric surgery, Gallstone disease, Metabolic surgery, Biliary disease, Ultrasound, Laparoscopic ultrasound
Medical subject headings
Cholelithiasis, Gallbladder Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Diagnostic proceduresDiagnostic test

    Also called Transabdominal ultrasound, Laparoscopic ultrasound

    In the same patients, we will do both transabdominal and laparoscopic ultrasound

Study groups in NCT07453186
Study groupRoleWhat they receive
Ultrasound examinationOtherNot described
Receives: Diagnostic Test: Diagnostic procedures

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gallbladder pathology (yes / no)

    Composite endpoint consisting of gallstones (yes/no), slugde (yes/no), micro- lithiasis (yes/no), diffuse gallbladder wall thickness over 3 mm (yes/no).

    Measured: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery

Secondary outcomes (1)
  1. Interobserver variability

    Interobserver agreement (Cohen's kappa)

    Measured: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2026
  2. Study start1 Apr 2026
  3. Primary completion1 Jun 2028 (estimated)
  4. Study completion1 Mar 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
Prospective observational diagnostic accuracy study with paired design.
Masking
None (open label)
Enrolment
130 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07453186
Sponsor's protocol ID
EsbjergH
Status last verified
May 2026
First submitted
25 Feb 2026
Last updated
2 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared due to national data protection regulations and institutional restrictions.

Questions about this trial

What is this clinical trial studying?

A study testing Diagnostic procedures in people with Gallstone Disease and Ultrasonic Diagnosis, run by Esbjerg Hospital - University Hospital of Southern Denmark at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Benjamin Petersen, M.D. (+45 79 18 57 14, benjamin.drejer.petersen@rsyd.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gallbladder pathology (yes / no) (time frame: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in